Clinical Trials Directory

Trials / Completed

CompletedNCT03684759

Sputum Validation for the Molecular Diagnosis of Respiratory Viral Infections in Cystic Fibrosis

Pilot Feasibility Study for Cystic Fibrosis Sputum Validation for the Molecular Diagnosis of Respiratory Viral Infections

Status
Completed
Phase
Study type
Observational
Enrollment
30 (actual)
Sponsor
University Hospital, Brest · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The aim of this pilot study is to demonstrate the feasibility of viral biomolecular diagnosis in sputum compared to nasopharyngeal swab in cystic fibrosis acute respiratory infection.

Detailed description

In cystic fibrosis (CF), patients face polymicrobial airway infections. Besides bacteria, viruses are now also considered as important agents in lung function deterioration. No strategy has been established on the optimal sampling for respiratory viral molecular diagnostic in CF. Nasopharyngeal swabs (NP) are recommended for respiratory viral screening in non-CF patients but are invasive and sometimes painful for patients. As sputa are non invasive and collected for bacterial monitoring in CF patients they could represent a convenient alternative to NP swabs. This study's aim is to define whether viral screening give concordant results between sputa and NP swabs.

Conditions

Timeline

Start date
2016-02-24
Primary completion
2017-02-06
Completion
2017-02-06
First posted
2018-09-26
Last updated
2018-09-26

Locations

3 sites across 1 country: France

Source: ClinicalTrials.gov record NCT03684759. Inclusion in this directory is not an endorsement.

Sputum Validation for the Molecular Diagnosis of Respiratory Viral Infections in Cystic Fibrosis (NCT03684759) · Clinical Trials Directory